Commercial transformation across European life sciences
Pharma, MedTech, Digital Health and AI.
Life Sciences Commercial Transformation in Europe: Strategy, Market Signals, and What Comes Next
Commercialization, regulation, AI, and operating-model shifts shaping pharma, MedTech, and digital health in Europe – from an operator’s perspective.
Weekly Life Sciences Signal
Weekly analysis of funding, regulation, AI, commercial moves, and execution signals shaping life sciences in Europe.
Europe Life Sciences Weekly Signal #45: The Moat Is Moving Beyond the Molecule
Week of 6–12 July 2026 Two British discovery platforms found larger pharmaceutical balance sheets this week. Astex licensed compounds from its breast-cancer discovery programme to Genentech. Myricx Bio, spun out of Imperial College London and the Francis Crick Institute, agreed to be acquired by Novartis for up to $1.5 billion. Both are commercial successes. Together,…
Europe Life Sciences Weekly Signal #44: The Label Is the Strategy
Week of 29 June – 5 July 2026 The headline number this week was a deal figure. Naturally. Life sciences still loves a large cheque almost as much as it loves pretending “strategic optionality” is a strategy. But the real value this week was not created in the deal room. It was created at the…
Europe Life Sciences Weekly Signal #43: The System Is Becoming the Product
Week of 22–28 June 2026 For a long time, life sciences companies could behave as if the product sat at the centre of everything. Develop the asset. Generate the evidence. Secure approval. Build the launch plan. Push adoption. That sequence still exists, of course. But it no longer explains where advantage is created. This week’s…
Get the Weekly Life Sciences Signal
Funding, regulation, AI, and strategic moves shaping life sciences in Europe in one sharp weekly read.
Strategic Perspectives on European Life Sciences
Life Sciences Market Intelligence
Funding, valuations, and strategic moves.
Commercialization & Go-to-Market
AI & Digital Health
About
Disrupting.healthcare is an independent publication focused on how commercial transformation actually happens in life sciences.
Operating models, market execution, AI, regulation, omnichannel and the European reality between global strategy and local adoption.
Piotr Wrzosinski, author and owner of disrupting.healthcare, is a life sciences commercial transformation leader with 20+ years of experience across pharma, MedTech, and consulting.